Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.
Tian, D., Battles, M.B., Moin, S.M., Chen, M., Modjarrad, K., Kumar, A., Kanekiyo, M., Graepel, K.W., Taher, N.M., Hotard, A.L., Moore, M.L., Zhao, M., Zheng, Z.Z., Xia, N.S., McLellan, J.S., Graham, B.S.(2017) Nat Commun 8: 1877-1877
- PubMed: 29187732 
- DOI: 10.1038/s41467-017-01858-w
- Primary Citation of Related Structures:  
- PubMed Abstract: 
A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab ...